Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122353 · ClinicalTrials.gov registry record · Phase 1
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
A Phase 1 study, sponsored by Tolmar.
- Completed
- Registry status
- Phase 1
- Development phase
- 699
- Enrollment target
NCT03122353: Completed Phase 1 study, sponsored by Tolmar.
NCT03122353 is a Phase 1 study that has completed, run by Tolmar. The registered enrollment target is 699 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1065% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122353, a Phase 1 study, has completed, sponsored by Tolmar.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 699 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.
Primary Outcome
To evaluate the change in clinical outcome of patients exposed to Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%, Taclonex and Vehicle for scalp psoriasis. From baseline to end of study.
Interventions
- DRUG Placebo
- DRUG Taclonex
- DRUG Calcipotriene and betamethasone suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 699 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 1 |
What the finished NCT03122353 record still lists
NCT03122353 is an interventional study that assigns participants to a tested intervention. The registered 699 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1065% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03122353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03122353 about?
NCT03122353 is a clinical study titled "BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis". This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.
What is the current status of trial NCT03122353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 699 participants. The study started on 2017-04-11. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT03122353?
The interventions under investigation include: Placebo (DRUG), Taclonex (DRUG), Calcipotriene and betamethasone suspension (DRUG).
Who is sponsoring clinical trial NCT03122353?
This trial is sponsored by Tolmar, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03122353's enrollment target sits among peer trials
699 20th of 2000 higher than 1,981 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07187115 · 699 participants · NA
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI